LAMB3 and junctional epidermolysis bullosa: More recently, CEAs have enabled epithelial gene therapy in patients with junctional epidermolysis bullosa (JEB), a blistering disease in which epithelia are inadequately anchored to the basement membrane owing to mutations in genes encoding laminin 332 (LAMA3, LAMB3, and LAMC2).